 Pfizer Inc. PFE, -0.77 and BioNTech SE BNTX, -1.63 said Monday that they asked the Food and Drug Administration to authorize their updated COVID-19 vaccine as the third dose for children between the ages of 6 months and 5 years old. Children in this age group receive three doses as their primary series of shots. 